New data on secondary stroke prevention: In a phase 3 trial, Asundexian reduced the recurrence rate (6.2% vs. 8.4%) in addition to providing antiplatelet effects, without increasing the risk of bleeding.
www.nejm.org/doi/full/10....
#Stroke #Neurology #neuroskyence
